• 123: Previewing Cleveland Clinic's Epilepsy Summit

  • Sep 6 2024
  • Duración: 23 m
  • Podcast

123: Previewing Cleveland Clinic's Epilepsy Summit

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.


    In this episode, epilepsy expert Imad Najm, MD, PhD, sat down to discuss the upcoming Cleveland Clinic Epilepsy Summit, an educational symposium that takes place September 11-15, in Cleveland, Ohio. Najm, who serves as the director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute, spoke about the objectives and goals of the meeting, including updates on sEEG, epilepsy surgery, treatments for drug-resistant epilepsy, and gene therapy. In addition, he provided an overview of the latest advances in epilepsy surgery, genetics, and seizure controlling approaches. Furthermore, he spoke on some of the educational challenges with adjusting to changes in neurosurgery, the potential benefits and limitations of gene therapy, and the future of epilepsy treatment.

    Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

    Episode Breakdown:
    • 1:10 – Mission and goals of Epilepsy Summit
    • 3:05 – Overviewing sessions and educational attainment
    • 4:55 – Changes to epilepsy surgery, advances over the years
    • 9:15 – Neurology News Minute
    • 11:50 – Learning curve for understanding new epilepsy surgery tactics
    • 13:50 – Closing thoughts on the upcoming meeting
    • 15:50 – Potential benefits and challenges to gene therapy for epilepsy

    The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

    • EMA Accepts Marketing Authorization Application for Huntington Disease Agent Pridopidine
    • BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 HERCULES Study of Non-Relapsing Secondary Progressive MS
    • FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07

    Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
    Más Menos
activate_WEBCRO358_DT_T2
Enfermedades Físicas Hygiene & Healthy Living Ciencia
Más Menos

Lo que los oyentes dicen sobre 123: Previewing Cleveland Clinic's Epilepsy Summit

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles